ACADIA Pharmaceuticals Inc. Second Quarter 2004 Earnings Conference Call
SAN DIEGO--(BUSINESS WIRE)--Aug. 5, 2004--ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report second quarter 2004 financial results on Wednesday, August 11, 2004, after the U.S. financial markets close.
ACADIA will host a conference call and webcast on Wednesday, August 11, 2004 at 4:30 p.m. EDT to discuss financial results for the second quarter ended June 30, 2004. Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer, will also provide an update on the Company's progress.
The conference call may be accessed by dialing 800-901- 5231 for participants from the United States or Canada and 617-786-2961 for international callers (reference participant passcode 69887488). The conference call will also be webcast live on ACADIA's website at http://www.acadia-pharm.com, under the investor relations section, and will be archived there until August 25, 2004
This call is being webcast by Thomson/CCBN and can be accessed at Acadia's Web site at www.acadia-pharm.com.
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative science to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA currently has five drug programs in clinical and preclinical development directed at large unmet medical needs and major commercial markets, including Parkinson's disease, schizophrenia, chronic pain, and glaucoma. Using its proprietary drug discovery platform, ACADIA has discovered all of the drug candidates in its product pipeline. ACADIA's corporate headquarters and biological research facilities are located in San Diego, California and its chemistry research facilities are located in Copenhagen, Denmark.
CONTACT: ACADIA Pharmaceuticals, Inc.
Thomas H. Aasen, 858-558-2871
SOURCE: ACADIA Pharmaceuticals Inc.